Table 2.

Approved marketed JAKinibs.

Name	Specificity	Approved indications	Elimination
Tofacitinib	JAK1/JAK3/(JAK2)	RA, PsA, UC, pA JIA	metab. by Cyto.
Baricitinib	JAK1, JAK2	RA	urine excretion
Ruxolitinib	JAK1, JAK2	MPN, acute GVHD	metab. by Cyto.
Peficitinib	pan-JAK	RA (Japan)	metab. indt of cyto
Fedratinib	JAK2, Flt3	MPN	metab. by Cyto.
Upadacitinib	JAK1	RA, PsA	metab. by Cyto.
Filgotinib	JAK1	RA (Europe, Japan)	urine excretion

RA, rheumatoid arthritis; PsA, psoriasis arthritis; UC, ulcerative colitis; pA JIA, polyarticular juvenile idiopathic arthritis; MPN, myeloproliferative neoplasm; GVHD, graft versus host disease; metab. by cyto, metabolized by cytochrome P450 complex; metab. indt of cyto, metabolism independent of cytochrome P450 complex.